Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 7, 2011, Pages 1675-1681

  Bellanger, Natacha ^a,c   Orsoni, Alexina ^a,c   Julia, Zélie ^a,c   Fournier, Natalie ^d,e   Frisdal, Eric ^a,c   Duchene, Emilie ^a,b,c   Bruckert, Eric ^a,b,c   Carrie, Alain ^a,c   Bonnefont Rousselot, Dominique ^a,f   Pirault, John ^a,c   Saint Charles, Flora ^a,c   Chapman, M John ^a,c   Lesnik, Philippe ^a,c   Le Goff, Wilfried ^a,c   Guerin, Maryse ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ABC transporter; lipoproteins; macrophages; metabolism; receptors

Indexed keywords

ABC TRANSPORTER G1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; ATHEROGENESIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MALE; PARTICLE SIZE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 79959747118     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.227181     Document Type: Article

References (35)

1. Goldstein JL, Brown MS. Familial hypercholesterolemia: pathogenesis of a receptor disease. Johns Hopkins Med J. 1978;143:8-16. (Pubitemid 9002144)
2. Jansen AC, van Wissen S, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol. 2002;13:165-171. (Pubitemid 34280768)
3. Williams KJ. Molecular processes that handle-and mishandle-dietary lipids. J Clin Invest. 2008;118:3247-3259.
4. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982-49988. (Pubitemid 36014449)
5. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161:245-254. (Pubitemid 34219176)
6. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300. (Pubitemid 37430562)
7. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42:1173-1179. (Pubitemid 32744239)
8. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774-9779. (Pubitemid 38869312)
9. Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, de la Llera-Moya M, Rothblat GH. Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol. 1999;10:329-339. (Pubitemid 29419690)
10. Frenais R, Ouguerram K, Maugeais C, Marchini JS, Benlian P, Bard JM, Magot T, Krempf M. Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res. 1999; 40:1506-1511. (Pubitemid 29379992)
11. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer HB Jr. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1992;12:843-848.
12. Miltiadous G, Cariolou MA, Elisaf M. HDL cholesterol levels in patients with molecularly defined familial hypercholesterolemia. Ann Clin Lab Sci. 2002;32:50-54. (Pubitemid 34137433)
13. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374. (Pubitemid 44394906)
14. Ottestad IO, Halvorsen B, Balstad TR, Otterdal K, Borge GI, Brosstad F, Myhre AM, Ose L, Nenseter MS, Holven KB. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J Nutr. 2006;136: 877-881.
15. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, Chapman MJ, Guerin M. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol. 2009; 29:268-275.
16. Bagdade JD, Lane JT, Stone N, Ritter MC, Subbaiah PV. Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. J Lipid Res. 1990;31:1263-1269. (Pubitemid 20224724)
17. Guerin M, Dolphin PJ, Chapman MJ. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb. 1994;14:679-685.
18. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb. 1991;11: 797-804.
19. Giral P, Kahn JF, Andre JM, Carreau V, Dourmap C, Bruckert E, Chapman MJ. Carotid atherosclerosis is not related to past tuberculosis in hypercholesterolemic patients. Atherosclerosis. 2007;190: 150-155. (Pubitemid 44908309)
20. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189-197. (Pubitemid 30048363)
21. Mweva S, Paul JL, Cambillau M, Goudouneche D, Beaune P, Simon A, Fournier N. Comparison of different cellular models measuring in vitro the whole human serum cholesterol efflux capacity. Eur J Clin Invest. 2006;36:552-559. (Pubitemid 44086770)
22. Therond P, Couturier M, Demelier JF, Lemonnier F. Simultaneous determination of the main molecular species of soybean phosphatidylcholine or phosphatidylethanolamine and their corresponding hydroperoxides obtained by lipoxygenase treatment. Lipids. 1993;28:245-249. (Pubitemid 23086577)
23. Catalano G, Duchene E, Julia Z, Le Goff W, Bruckert E, Chapman MJ, Guerin M. Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects. J Lipid Res. 2008;49:635-643.
24. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29: 1930-1936.
25. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2010;364:127-135.
26. Miida T, Inano K, Yamaguchi T, Tsuda T, Okada M. LpA-I levels do not reflect preα1-HDL levels in human plasma. Atherosclerosis. 1997;133: 221-226. (Pubitemid 27373499)
27. Miida T, Nakamura Y, Inano K, Matsuto T, Yamaguchi T, Tsuda T, Okada M. Preα1-high-density lipoprotein increases in coronary artery disease. Clin Chem. 1996;42:1992-1995. (Pubitemid 26415351)
28. Tsimihodimos V, Gazi I, Filippatos T, Kostapanos M, Lagos K, Kostara C, Tellis CC, Elisaf M, Tselepis AD. Plasma triglyceride levels and body mass index values are the most important determinants of preα-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis. 2009;208:506-511.
29. Attia N, Fournier N, Vedie B, Cambillau M, Beaune P, Ziegler O, Grynberg A, Paul JL, Guerci B. Impact of android overweight or obesity and insulin resistance on basal and postprandial SR-BI and ABCA1-mediated serum cholesterol efflux capacities. Atherosclerosis. 2009;209: 422-429.
30. Pussinen P, Jauhianinen M, Metso J, Tyynela J, Ehnholm C. Pig plasma phospholipid transfer protein facilitates HDL interconversion. J Lipid Res. 1995;36:975-985.
31. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, Cartland S, Packianathan M, Kritharides L, Jessup W. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol. 2006;26:534-540.
32. Jian B, de la Llera-Moya M, Royer L, Rothblat G, Francone O, Swaney JB. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res. 1997;38:734-744. (Pubitemid 27194924)
33. Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000;275:36596-36604. (Pubitemid 32002059)
34. Tchoua U, Gillard BK, Pownall HJ. HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis. 2009;209:430-435.
35. Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, Van Berkel TJ, Kastelein JJ, Van Eck M, Kuivenhoven JA. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364: 136-145.